Arbor Biotechnologies has closed $73.9m for its gene editing therapeutic pipeline aimed at liver and central nervous system ...
Prime Medicine and Beam Therapeutics had common origins in gene editing. Now they're both pursuing treatments for the same ...
Researchers are using gene editing techniques to introduce beneficial traits like polled and disease resistance, as well as ...
As other gene editing programs fold or get sold, Arbor Biotechnologies has secured $73.9 million to advance its lead ...
The Times of Israel on MSN2d
Israeli researchers use gene editing to eliminate 50% of head, neck tumors in miceTel Aviv University scientists say that they can inject CRISPR genetic 'molecular scissors' to shrink tumors by 90%; ...
The gene therapy world is in turmoil, but Arbor, armed with more than a billion dollars in partnerships and raises, is going forward.
The round will fund a “one-and-done” treatment for a rare kidney condition that its CEO says can address concerns patients ...
An animal geneticist told Kansas cattle producers recently that a gene editing technique is a safe option for shortening the ...
The firm will use the funds to develop its lead candidate in primary hyperoxaluria type 1 and other pipeline products in liver and CNS disorders.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback